Literature DB >> 19944277

Critical care issues in oncological surgery patients.

Sanam Ahmed1, John M Oropello.   

Abstract

As life expectancy increases and advances in cancer treatment more often convert deadly conditions into more chronic diseases, the surgical intensivist can expect to be faced with greater numbers of oncology patients undergoing aggressive surgical treatments for curative intent, prolonging survival, or primarily palliation by alleviating obstruction, infection, bleeding, or pain. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) are a paradigm for the emerging field of multimodal aggressive oncological surgery. This article describes the CRS/HIPEC technique, and discusses the most common postoperative complications and critical care issues in these patients, including anastomotic leaks, intestinal perforation, abscesses, and intra-abdominal bleeding. The leading cause of mortality is sepsis leading to multiple organ failure, and such patients are at particularly higher risk due to the extensive CRS and HIPEC. The intensivist must be vigilant to ensure that source control is not overlooked. This process is a very difficult one, made even more challenging by the blunting of physiologic responses and the frequent absence of the classic acute abdomen.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19944277     DOI: 10.1016/j.ccc.2009.10.004

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  6 in total

1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease.

Authors:  Wenceslao Vásquez Jiménez; Luis González Bayón; José Luis García-Sabrido; Santiago González Moreno
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

2.  Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) from a Tertiary Cancer Center in India.

Authors:  Naveen Padmanabhan; Barath Raj Kumar; Ansar Pullampara Pookunju; Ayyapan Srinivasan; Vikash Mahajan
Journal:  J Clin Diagn Res       Date:  2015-06-01

3.  Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC).

Authors:  Timothy J Cooksley; Philip Haji-Michael
Journal:  World J Surg Oncol       Date:  2011-12-19       Impact factor: 2.754

4.  Organ dysfunction in critically ill cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Silvio A Ñamendys-Silva; Paulina Correa-García; Francisco J García-Guillén; Horacio N López-Basave; Gonzalo Montalvo-Esquivel; Julia Texcocano-Becerra; Ángel Herrera-Gómez; Abelardo Meneses-García
Journal:  Oncol Lett       Date:  2015-01-30       Impact factor: 2.967

5.  Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Sumit Kapoor; Adel Bassily-Marcus; Rafael Alba Yunen; Parissa Tabrizian; Sabrine Semoin; Joseph Blankush; Daniel Labow; John Oropello; Anthony Manasia; Roopa Kohli-Seth
Journal:  World J Crit Care Med       Date:  2017-05-04

6.  Increased Plasma Levels of Danger-Associated Molecular Patterns Are Associated With Immune Suppression and Postoperative Infections in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Guus P Leijte; Hettie Custers; Jelle Gerretsen; Amon Heijne; Johannes Roth; Thomas Vogl; Gert J Scheffer; Peter Pickkers; Matthijs Kox
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.